Why the study?
Huoxin formula is a Traditional Chinese Medicine used for coronary heart disease, but its therapeutic mechanism on arterial functions needed exploration.
Does Huoxin formula improve arterial functions and reduce inflammatory biomarkers in patients with coronary heart disease?
Does Huoxin formula improve arterial functions and reduce inflammatory biomarkers in patients with coronary heart disease?
Huoxin formula added to standard therapy may attenuate the progression of carotid intima-media thickness and reduce systemic inflammation in patients with coronary heart disease.
May improve arterial function when added to standard CHD therapy; extends small RCT data but leaves open need for larger outcome trials.
Context: Huoxin formula is a Traditional Chinese Medicine for coronary heart disease (CHD) treatment.Objective: To explore the therapeutic mechanism of the Huoxin formula on arterial functions in CHD patients.Materials and methods: Fifty-eight CHD patients receiving cardiovascular drugs including β-receptor blocker, statins, and antiplatelet medications or others were randomized into intervention [additionally 13.5 g Huoxin formula granules dissolved in 150 mL warm water per time, twice a day (n = 30)] and control [only cardiovascular drugs (n = 28)] groups. Serum biomarkers (hs-CRP, IL-18, IL-17, TNF-α, MMP-9), and cardiovascular indicators of the common and internal carotid arteries (ICAs) were monitored before and after the treatments.Results: After 3 months of treatment, the increases of intima-media thicknesses (IMT) of the left and right common carotid arteries (CCAs) as well as of the left and right ICAs and the increases of the left and right cardio-ankle vascular index were all significantly (all p < 0.001) less in the intervention than in control group (all p < 0.001). Serum concentrations reductions of hs-CRP, IL-18, IL-17 and MMP9 (all p < 0.001) levels were higher in the intervention compared to the control group, which correlated with the changes of left ICA (hs-CRP: r = 0.581, p = 0.009; IL-18: r = 0.594, p = 0.007; IL-17: r = 0.575, p = 0.006).Discussion and conclusion: Since the Huoxin formula improved arterial functions and reduced inflammatory factor activities in CHD patients, a large-scale clinical trial is warranted.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: